STOCK TITAN

[S-8 POS] Exact Sciences Corp SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
S-8 POS
Rhea-AI Filing Summary

Insmed, Inc. (INSM) – Form 144 notice of proposed sale

The filing discloses that Michael A. Smith intends to sell 748 shares of Insmed common stock through Merrill Lynch on or about 11 July 2025. The shares carry an aggregate market value of $72,114, implying a reference price of roughly $96 per share. Insmed has 182,138,923 shares outstanding, so the planned sale represents only 0.0004 % of the float.

The form also lists insider transactions over the preceding three months: Smith sold 34,470 shares between 14 May 2025 and 5 June 2025 for gross proceeds of $2.4 million. Even these cumulative sales equal just 0.019 % of shares outstanding. All sales were made under Rule 144, which governs the resale of restricted or control securities.

No financing, earnings, or operational data accompany the filing; the document’s sole purpose is to give advance notice of this modest insider disposition and to certify that the seller is unaware of undisclosed material adverse information.

Insmed, Inc. (INSM) – Avviso di proposta di vendita secondo il Modulo 144

La comunicazione rivela che Michael A. Smith intende vendere 748 azioni ordinarie di Insmed tramite Merrill Lynch intorno al 11 luglio 2025. Le azioni hanno un valore di mercato complessivo di 72.114 dollari, corrispondente a un prezzo di riferimento di circa 96 dollari per azione. Insmed conta 182.138.923 azioni in circolazione, quindi la vendita prevista rappresenta solo lo 0,0004% del flottante.

Il modulo elenca anche le transazioni degli insider negli ultimi tre mesi: Smith ha venduto 34.470 azioni tra il 14 maggio 2025 e il 5 giugno 2025 per un ricavo lordo di 2,4 milioni di dollari. Anche queste vendite cumulative corrispondono a solo lo 0,019% delle azioni in circolazione. Tutte le vendite sono state effettuate ai sensi della Regola 144, che disciplina la rivendita di titoli soggetti a restrizioni o di controllo.

Non sono allegati dati finanziari, di utili o operativi; lo scopo del documento è esclusivamente quello di fornire un preavviso di questa modesta cessione da parte di un insider e di certificare che il venditore non è a conoscenza di informazioni materiali negative non divulgate.

Insmed, Inc. (INSM) – Aviso de propuesta de venta según el Formulario 144

La presentación revela que Michael A. Smith tiene la intención de vender 748 acciones ordinarias de Insmed a través de Merrill Lynch alrededor del 11 de julio de 2025. Las acciones tienen un valor de mercado agregado de 72,114 dólares, lo que implica un precio de referencia de aproximadamente 96 dólares por acción. Insmed tiene 182,138,923 acciones en circulación, por lo que la venta planeada representa solo el 0,0004% del flotante.

El formulario también lista transacciones de insiders en los últimos tres meses: Smith vendió 34,470 acciones entre el 14 de mayo de 2025 y el 5 de junio de 2025 por ingresos brutos de 2.4 millones de dólares. Incluso estas ventas acumuladas equivalen solo al 0,019% de las acciones en circulación. Todas las ventas se realizaron bajo la Regla 144, que regula la reventa de valores restringidos o de control.

No se acompañan datos financieros, de ganancias u operativos; el único propósito del documento es dar aviso previo de esta modesta disposición interna y certificar que el vendedor no tiene conocimiento de información material adversa no divulgada.

Insmed, Inc. (INSM) – Form 144 매도 예정 통지

신고서에 따르면 Michael A. Smith2025년 7월 11일경 Merrill Lynch를 통해 Insmed 보통주 748주를 매도할 계획임을 공개했습니다. 해당 주식의 총 시장 가치는 72,114달러로, 주당 약 96달러의 기준 가격을 의미합니다. Insmed의 유통 주식 수는 182,138,923주이며, 이번 매도는 유통 주식 대비 단지 0.0004%에 해당합니다.

해당 양식은 지난 3개월간 내부자 거래 내역도 나열하고 있는데, Smith는 2025년 5월 14일부터 6월 5일까지 34,470주를 매도해 총 240만 달러의 매출을 올렸습니다. 누적 매도량도 전체 발행 주식의 0.019%에 불과합니다. 모든 매도는 제한주식 또는 통제주식의 재판매를 규정하는 Rule 144에 따라 이루어졌습니다.

재무, 수익 또는 운영 데이터는 첨부되지 않았으며, 문서의 유일한 목적은 이와 같은 소규모 내부자 매도에 대한 사전 통지와 판매자가 미공개 중대한 부정적 정보를 알지 못함을 인증하는 것입니다.

Insmed, Inc. (INSM) – Avis de projet de vente selon le formulaire 144

Le dépôt révèle que Michael A. Smith a l’intention de vendre 748 actions ordinaires d’Insmed via Merrill Lynch aux alentours du 11 juillet 2025. Les actions ont une valeur marchande totale de 72 114 dollars, ce qui implique un prix de référence d’environ 96 dollars par action. Insmed compte 182 138 923 actions en circulation, la vente prévue ne représentant donc que 0,0004 % du flottant.

Le formulaire liste également les transactions d’initiés des trois derniers mois : Smith a vendu 34 470 actions entre le 14 mai 2025 et le 5 juin 2025 pour un produit brut de 2,4 millions de dollars. Même ces ventes cumulées ne représentent que 0,019 % des actions en circulation. Toutes les ventes ont été effectuées conformément à la règle 144, qui régit la revente de titres restreints ou sous contrôle.

Aucune donnée financière, de résultat ou opérationnelle n’accompagne ce dépôt ; l’unique but du document est de donner un préavis de cette modeste cession par un initié et de certifier que le vendeur n’a connaissance d’aucune information défavorable importante non divulguée.

Insmed, Inc. (INSM) – Mitteilung über geplanten Verkauf gemäß Formular 144

Die Einreichung offenbart, dass Michael A. Smith beabsichtigt, etwa am 11. Juli 2025 748 Aktien von Insmed über Merrill Lynch zu verkaufen. Die Aktien haben einen gesamtmarktwert von 72.114 US-Dollar, was einem Referenzpreis von etwa 96 US-Dollar pro Aktie entspricht. Insmed hat 182.138.923 ausstehende Aktien, sodass der geplante Verkauf nur 0,0004 % des Streubesitzes ausmacht.

Das Formular listet auch Insider-Transaktionen der letzten drei Monate auf: Smith verkaufte zwischen dem 14. Mai 2025 und dem 5. Juni 2025 34.470 Aktien und erzielte Bruttoerlöse von 2,4 Millionen US-Dollar. Selbst diese kumulativen Verkäufe entsprechen nur 0,019 % der ausstehenden Aktien. Alle Verkäufe erfolgten gemäß Rule 144, die den Weiterverkauf von beschränkten oder kontrollierten Wertpapieren regelt.

Es sind keine Finanz-, Ertrags- oder Betriebsdaten beigefügt; der alleinige Zweck des Dokuments besteht darin, diesen bescheidenen Insider-Verkauf vorab anzukündigen und zu bestätigen, dass dem Verkäufer keine nicht offengelegten wesentlichen negativen Informationen bekannt sind.

Positive
  • Transparency and regulatory compliance: Filing shows the insider is following Rule 144 procedures, reinforcing good governance.
  • Immaterial share volume: Planned sale equals only 0.0004 % of shares outstanding, limiting dilution or market impact.
Negative
  • Continued insider selling: Cumulative 34,470 shares sold in the last three months may be perceived as diminished insider confidence, even if economically small.

Insights

TL;DR: Small Rule 144 sale—neutral; signals routine liquidity, not a strategic shift.

The proposed 748-share sale is de-minimis versus Insmed’s 182 million share base, and cumulative recent sales remain immaterial at ~0.02 %. Such filings are procedural for affiliates seeking liquidity after equity compensation. There is no indication of operational issues, and the certification explicitly states no undisclosed negative information. From a valuation or sentiment standpoint, the filing is neutral; volumes are far too small to influence supply–demand dynamics or imply management pessimism. Investors monitoring executive ownership trends may note continued divestiture, yet the scale does not alter the investment thesis.

TL;DR: Routine compliance disclosure; transparency positive, but insider selling can raise minor perception risk.

Form 144 demonstrates adherence to SEC resale rules and timely disclosure, a governance positive. However, ongoing insider disposals—though quantitatively trivial—can invite scrutiny over executive confidence. Because the seller affirms lack of material non-public information and volumes are immaterial, I view the governance impact as largely neutral with a slight negative optics element.

Insmed, Inc. (INSM) – Avviso di proposta di vendita secondo il Modulo 144

La comunicazione rivela che Michael A. Smith intende vendere 748 azioni ordinarie di Insmed tramite Merrill Lynch intorno al 11 luglio 2025. Le azioni hanno un valore di mercato complessivo di 72.114 dollari, corrispondente a un prezzo di riferimento di circa 96 dollari per azione. Insmed conta 182.138.923 azioni in circolazione, quindi la vendita prevista rappresenta solo lo 0,0004% del flottante.

Il modulo elenca anche le transazioni degli insider negli ultimi tre mesi: Smith ha venduto 34.470 azioni tra il 14 maggio 2025 e il 5 giugno 2025 per un ricavo lordo di 2,4 milioni di dollari. Anche queste vendite cumulative corrispondono a solo lo 0,019% delle azioni in circolazione. Tutte le vendite sono state effettuate ai sensi della Regola 144, che disciplina la rivendita di titoli soggetti a restrizioni o di controllo.

Non sono allegati dati finanziari, di utili o operativi; lo scopo del documento è esclusivamente quello di fornire un preavviso di questa modesta cessione da parte di un insider e di certificare che il venditore non è a conoscenza di informazioni materiali negative non divulgate.

Insmed, Inc. (INSM) – Aviso de propuesta de venta según el Formulario 144

La presentación revela que Michael A. Smith tiene la intención de vender 748 acciones ordinarias de Insmed a través de Merrill Lynch alrededor del 11 de julio de 2025. Las acciones tienen un valor de mercado agregado de 72,114 dólares, lo que implica un precio de referencia de aproximadamente 96 dólares por acción. Insmed tiene 182,138,923 acciones en circulación, por lo que la venta planeada representa solo el 0,0004% del flotante.

El formulario también lista transacciones de insiders en los últimos tres meses: Smith vendió 34,470 acciones entre el 14 de mayo de 2025 y el 5 de junio de 2025 por ingresos brutos de 2.4 millones de dólares. Incluso estas ventas acumuladas equivalen solo al 0,019% de las acciones en circulación. Todas las ventas se realizaron bajo la Regla 144, que regula la reventa de valores restringidos o de control.

No se acompañan datos financieros, de ganancias u operativos; el único propósito del documento es dar aviso previo de esta modesta disposición interna y certificar que el vendedor no tiene conocimiento de información material adversa no divulgada.

Insmed, Inc. (INSM) – Form 144 매도 예정 통지

신고서에 따르면 Michael A. Smith2025년 7월 11일경 Merrill Lynch를 통해 Insmed 보통주 748주를 매도할 계획임을 공개했습니다. 해당 주식의 총 시장 가치는 72,114달러로, 주당 약 96달러의 기준 가격을 의미합니다. Insmed의 유통 주식 수는 182,138,923주이며, 이번 매도는 유통 주식 대비 단지 0.0004%에 해당합니다.

해당 양식은 지난 3개월간 내부자 거래 내역도 나열하고 있는데, Smith는 2025년 5월 14일부터 6월 5일까지 34,470주를 매도해 총 240만 달러의 매출을 올렸습니다. 누적 매도량도 전체 발행 주식의 0.019%에 불과합니다. 모든 매도는 제한주식 또는 통제주식의 재판매를 규정하는 Rule 144에 따라 이루어졌습니다.

재무, 수익 또는 운영 데이터는 첨부되지 않았으며, 문서의 유일한 목적은 이와 같은 소규모 내부자 매도에 대한 사전 통지와 판매자가 미공개 중대한 부정적 정보를 알지 못함을 인증하는 것입니다.

Insmed, Inc. (INSM) – Avis de projet de vente selon le formulaire 144

Le dépôt révèle que Michael A. Smith a l’intention de vendre 748 actions ordinaires d’Insmed via Merrill Lynch aux alentours du 11 juillet 2025. Les actions ont une valeur marchande totale de 72 114 dollars, ce qui implique un prix de référence d’environ 96 dollars par action. Insmed compte 182 138 923 actions en circulation, la vente prévue ne représentant donc que 0,0004 % du flottant.

Le formulaire liste également les transactions d’initiés des trois derniers mois : Smith a vendu 34 470 actions entre le 14 mai 2025 et le 5 juin 2025 pour un produit brut de 2,4 millions de dollars. Même ces ventes cumulées ne représentent que 0,019 % des actions en circulation. Toutes les ventes ont été effectuées conformément à la règle 144, qui régit la revente de titres restreints ou sous contrôle.

Aucune donnée financière, de résultat ou opérationnelle n’accompagne ce dépôt ; l’unique but du document est de donner un préavis de cette modeste cession par un initié et de certifier que le vendeur n’a connaissance d’aucune information défavorable importante non divulguée.

Insmed, Inc. (INSM) – Mitteilung über geplanten Verkauf gemäß Formular 144

Die Einreichung offenbart, dass Michael A. Smith beabsichtigt, etwa am 11. Juli 2025 748 Aktien von Insmed über Merrill Lynch zu verkaufen. Die Aktien haben einen gesamtmarktwert von 72.114 US-Dollar, was einem Referenzpreis von etwa 96 US-Dollar pro Aktie entspricht. Insmed hat 182.138.923 ausstehende Aktien, sodass der geplante Verkauf nur 0,0004 % des Streubesitzes ausmacht.

Das Formular listet auch Insider-Transaktionen der letzten drei Monate auf: Smith verkaufte zwischen dem 14. Mai 2025 und dem 5. Juni 2025 34.470 Aktien und erzielte Bruttoerlöse von 2,4 Millionen US-Dollar. Selbst diese kumulativen Verkäufe entsprechen nur 0,019 % der ausstehenden Aktien. Alle Verkäufe erfolgten gemäß Rule 144, die den Weiterverkauf von beschränkten oder kontrollierten Wertpapieren regelt.

Es sind keine Finanz-, Ertrags- oder Betriebsdaten beigefügt; der alleinige Zweck des Dokuments besteht darin, diesen bescheidenen Insider-Verkauf vorab anzukündigen und zu bestätigen, dass dem Verkäufer keine nicht offengelegten wesentlichen negativen Informationen bekannt sind.


As filed with the Securities and Exchange Commission on July 11, 2025
Registration No. 333-273572
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________________________________________

Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-273572
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
_____________________________________________________________________________

EXACT SCIENCES CORPORATION
(Exact name of registrant as specified in its charter)
_____________________________________________________________________________

Delaware
(State or other jurisdiction of incorporation or organization)
02-0478229
(I.R.S. Employer Identification No.)
5505 Endeavor Lane, Madison, Wisconsin
(Address of principal executive offices)
53719
(Zip Code)
Exact Sciences Corporation 2010 Omnibus Long-Term Incentive Plan (as amended and restated effective July 27, 2017)
Exact Sciences Corporation 2019 Omnibus Long-Term Incentive Plan
Exact Sciences Corporation 2025 Omnibus Long-Term Incentive Plan
(Full title of the plan)
James Herriott
Senior Vice President, General Counsel and Secretary
Exact Sciences Corporation
5505 Endeavor Lane
Madison, WI 53719
(Name and address of agent for service)
(608) 284-5700
(Telephone number, including area code, of agent for service)
_____________________________________________________________________________
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 7(a)(2)(B) of the Securities Act.
_____________________________________________________________________________




EXPLANATORY NOTE
Exact Sciences Corporation, a Delaware corporation (the “Company” or “Registrant”) has previously registered shares of the Registrant’s common stock, par value $0.01 per share (the “Common Stock”) to be issued under the Exact Sciences Corporation 2010 Omnibus Long-Term Incentive Plan (As Amended and Restated Effective July 27, 2017) (the “2010 Plan”) and the Exact Sciences Corporation 2019 Omnibus Long-Term Incentive Plan (as last amended on June 8, 2023, the “2019 Plan”, and together with the 2010 Plan, the “Prior Plans”). In connection with the Prior Plans, the Registrant has previously filed with the Securities and Exchange Commission (the “SEC”) (i) a Registration Statement on Form S-8 on August 17, 2010 (File No. 333-168909), (ii) a Registration Statement on Form S-8 on August 2, 2013 (File No. 333-190350), (iii) a Registration Statement on Form S-8 on October 30, 2015 (File No. 333-207703), (iv) a Registration Statement on Form S-8 on July 28, 2017 (File No. 333-219553), (v) Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-219553 on July 31, 2019, (vi) a Registration Statement on Form S-8 (File No. 333-232916) on July 31, 2019, (vii) a Registration Statement on Form S-8 (File No. 333-234608) on November 8, 2019, (viii) a Registration Statement on Form S-8 (File No. 333-266471) on August 2, 2022, and (ix) a Registration Statement on Form S-8 (File No. 333-273572) on August 1, 2023 (collectively, the “Prior Registration Statements”).
On June 12, 2025 (the “Approval Date”), the stockholders of the Registrant approved the Exact Sciences Corporation 2025 Omnibus Long-Term Incentive Plan (the “2025 Plan”). Pursuant to the terms of the 2025 Plan, the maximum number of shares of Common Stock that may be issued under the 2025 Plan shall be the sum of (i) 11,896,525 newly available shares of Common Stock less the number of shares of Common Stock the Registrant granted under the 2019 Plan between March 31, 2025 and June 12, 2025 (the “New Shares”) plus (ii) any shares of Common Stock subject to stock options or other awards granted under the Prior Plans as of the Approval Date that expire or are terminated, surrendered or forfeited for any reason without the issuance of shares of Common Stock (the “Rollover Shares”). No further awards will be granted under the Prior Plans on or after the Approval Date.
The Registrant is filing this Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 (this “Post-Effective Amendment”) pursuant to Securities Act Forms Compliance and Disclosure Interpretation Question 126.43, reflecting the interpretative position of the Division of Corporation Finance of the SEC to amend the Registration Statement to also cover the registration of the Rollover Shares under the 2025 Plan (to the extent such shares are, or become no longer issuable under the Prior Plans and instead are, or become, issuable under the 2025 Plan).
Contemporaneously with the filing of this Post-Effective Amendment, the Registrant is filing a registration statement on Form S-8 to register the New Shares that have become available for offer or sale pursuant to the 2025 Plan. No additional securities are being registered by this Post-Effective Amendment.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
Item 1. Plan Information.

The information required by this Item 1 is omitted from this filing and is included in documents sent or provided to participants of the 2025 Plan in accordance with Rule 428(b)(1) of the Securities Act and the Note to Part I of Form S-8. These documents and the documents incorporated by reference in the applicable Registration Statement pursuant to Item 3 of Part II of this form, taken together, constitute prospectuses that meet the requirements of Section 10(a) of the Securities Act.
Item 2. Registrant Information and Employee Plan Annual Information.
The information required by this Item 2 is omitted from this filing and is included in documents sent or provided to participants of the 2025 Plan in accordance with Rule 428(b)(1) of the Securities Act and the Note to Part I of Form S-8. These documents and the documents incorporated by reference in the applicable Registration Statement pursuant to Item 3 of Part II of this form, taken together, constitute prospectuses that meet the requirements of Section 10(a) of the Securities Act.




PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

The following documents have been filed by Exact Sciences Corporation, a Delaware corporation (the "Company" or "Registrant") with the U.S. Securities and Exchange Commission (the "Commission") and are incorporated herein by reference:
Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 19, 2025;
Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Commission on May 1, 2025;
Current Reports on Form 8-K, filed with the Commission on January 6, 2025, January 13, 2025, April 29, 2025, and June 16, 2025;
the portions of the Registrant’s Definitive Proxy Statement on Schedule 14A filed on April 29, 2025 that are specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024; and
The description of the Registrant’s Common Stock contained in the Registrant’s registration statement on Form 8-A, filed with the SEC pursuant to Section 12(g) of the Exchange Act on December 26, 2000, as updated by Exhibit 4.6 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed on February 16, 2021, including any amendments or reports filed for the purpose of updating such description.
All reports and other documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date hereof, and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports and documents. The Registrant is not incorporating by reference any reports or documents or portions thereof that are not considered to be “filed” with the Commission.

Any statement contained herein or in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated herein by reference modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Item 4. Description of Securities.
Not applicable.
Item 5. Interests of Named Experts and Counsel.
Not applicable.
Item 6. Indemnification of Directors and Officers.
Section 102(b)(7) of the General Corporation Law of the State of Delaware (the “DGCL”), allows a corporation to provide in its certificate of incorporation that a director or officer of the corporation will not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, except where the director or officer breached his or her duty of loyalty to the corporation or its stockholders, the director or officer failed to act in good faith or engaged in intentional misconduct or knowingly violated a law, the



director authorized the payment of a dividend or approved a stock repurchase in violation of the DGCL, or the director or officer obtained an improper personal benefit, or, solely in the case of an officer, in any action by or in the right of the corporation. The Company’s amended and restated certificate of incorporation (the “Certificate of Incorporation”) provides for this limitation of liability solely for its directors.
Section 145 of the DGCL (“Section 145”) provides that a Delaware corporation may indemnify any person who was or is a party, or is threatened to be made a party, to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was an officer, director, employee or agent of such corporation or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation’s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was illegal. A Delaware corporation may indemnify any persons who were or are a party to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person is or was a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit, provided such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation’s best interests, provided that no indemnification is permitted without judicial approval if the officer, director, employee or agent is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him or her against the expenses which such officer or director has actually and reasonably incurred.
Section 145 further authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise, against any liability asserted against him or her and incurred by him or her in any such capacity, or arising out of his or her status as such, whether or not the corporation would otherwise have the power to indemnify him or her under Section 145.
In addition, the Certificate of Incorporation provides that the Company shall indemnify each person who was or is a party, or is threatened to be made a party to, any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such person is or was, or has agreed to become, one of the Company’s directors or officers or is or was serving, or has agreed to serve, at the Company’s request as a director, officer or trustee of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, against all expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding and any appeal therefrom, if he acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the Company, and with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.
All of the Company’s directors and officers are covered by insurance policies maintained by the Company against specified liabilities for actions taken in their capacities as such, including liabilities under the Securities Act. Additionally, insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
Item 7. Exemption from Registration Claimed.
Not applicable.




Item 8. Exhibits
Exhibit
Number
Exhibit Title
4.1
Sixth Amended and Restated Certificate of Incorporation of the Registrant (previously filed as Exhibit 3.3 to the Registrant's Form S-1 (File No. 333-48812) filed on December 4, 2000, which is incorporated herein by reference)
4.2
Certificate of Amendment to Sixth Amended and Restated Certificate of Incorporation of the Registrant (previously filed as Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed on July 24, 2020, which is incorporated herein by reference)
4.3
Certificate of Amendment to Sixth Amended and Restated Certificate of Incorporation of Exact Sciences Corporation (previously filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on June 12, 2023, which is incorporated herein by reference)
4.4
Seventh Amended and Restated By-Laws of the Registrant, dated June 9, 2023 (previously filed as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed on June 12, 2023, which is incorporated herein by reference)
4.5
Exact Sciences Corporation 2025 Omnibus Long-Term Incentive Plan, (previously filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on June 16, 2025, which is incorporated herein by reference)
4.6
Exact Sciences Corporation 2010 Omnibus Long-Term Incentive Plan (As Amended and Restated Effective July 27, 2017) (previously filed as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the period ended September 30, 2017, which is incorporated herein by reference)
4.7
Exact Sciences Corporation 2019 Omnibus Long-Term Incentive Plan (previously filed as Exhibit 4.4 to the Registrant’s Registration Statement on Form S-8 filed on July 31, 2019, which is incorporated herein by reference)
4.8
Amendment No. 1 to Exact Sciences Corporation 2019 Omnibus Long-Term Incentive Plan (previously filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on June 9, 2022, which is incorporated herein by reference)
4.9
Amendment No. 2 to Exact Sciences Corporation 2019 Omnibus Long-Term Incentive Plan (previously filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on June 12, 2023, which is incorporated herein by reference)
5.1
Opinion of K&L Gates LLP, filed herewith
23.1
Consent of PricewaterhouseCoopers LLP, filed herewith
23.2
Consent of K&L Gates LLP (contained in Exhibit 5.1 hereto and filed herewith)
Item 9. Undertakings
A. The undersigned Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement; and
(iii) To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;



provided, however, that paragraphs (A)(1)(i) and (A)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.
(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
B. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefits plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
C. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that, in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.




SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Madison, State of Wisconsin, on July 11, 2025.
EXACT SCIENCES CORPORATION

By:/s/ Kevin T. Conroy
Kevin T. Conroy
President, Chief Executive Officer and Chairman

Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment has been signed by the following persons in the capacities and on the dates indicated.




NameTitleDate
/s/ Kevin T. ConroyPresident, Chief Executive Officer and Chairman (Principal Executive Officer)
July 11, 2025
Kevin T. Conroy
/s/ Aaron Bloomer
Executive Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
July 11, 2025
Aaron Bloomer
/s/ Michael Barber
Director
July 11, 2025
Michael Barber
/s/ Paul Clancy
Director
July 11, 2025
Paul Clancy
/s/ D. Scott CowardDirector
July 11, 2025
D. Scott Coward
/s/ James E. DoyleDirector
July 11, 2025
James E. Doyle
/s/ Daniel J. LevangieDirector
July 11, 2025
Daniel J. Levangie
/s/ Shacey Petrovic
Director
July 11, 2025
Shacey Petrovic
/s/ Kimberly Popovits
Director
July 11, 2025
Kimberly Popovits
/s/ Leslie Trigg
Director
July 11, 2025
Leslie Trigg
/s/ Katherine S. Zanotti
Director
July 11, 2025
Katherine S. Zanotti


FAQ

How many Insmed (INSM) shares are being sold under this Form 144?

748 common shares are scheduled for sale on or about 11 July 2025.

What is the value of the proposed INSM share sale?

The aggregate market value disclosed is $72,114.

Who is the selling insider in this INSM Form 144?

The seller is Michael A. Smith, as identified in the past-sales section.

How significant are the insider sales relative to Insmed’s share count?

The upcoming sale represents 0.0004 % of the 182,138,923 shares outstanding; past 3-month sales total 0.019 %.

Which broker will handle the transaction?

The filing names Merrill Lynch, 1800 K St NW, Washington DC as broker.
Exact Sciences Corp

NASDAQ:EXAS

EXAS Rankings

EXAS Latest News

EXAS Latest SEC Filings

EXAS Stock Data

9.90B
186.21M
1.07%
100.78%
5.74%
Diagnostics & Research
Services-medical Laboratories
Link
United States
MADISON